U.S., July 8 -- ClinicalTrials.gov registry received information related to the study (NCT07686263) titled 'Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia' on June 30.
Brief Summary: The purpose of the study is to evaluate the relapse prevention of KarXT in the treatment of participants with Schizophrenia
Study Start Date: Sept. 03
Study Type: INTERVENTIONAL
Condition:
Schizophrenia
Intervention:
DRUG: Xanomeline/Trospium Chloride
Specified dose on specified days
DRUG: Placebo
Specified dose on specified days
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Disclaimer: Curated by HT Syndication....